Lutetium-177-PSMA-617 in First-Line mHSPC and Its Impact on PSA Depth, Undetectable Rates, and Time to Progression - Fred Saad
Fred Saad
Fred Saad presents PSMAddition trial data, covering PSA response endpoints from the phase 3 study of lutetium-177 PSMA-617 added to ADT plus an ARPI in m HSPC patients.
A Multicenter Trial on Imaging-Guided Radiation Decisions in Biochemically Recurrent Prostate Cancer - Vidit Sharma
Vidit Sharma
Vidit Sharma describes a randomized trial testing whether salvage radiation to the prostate fossa can be safely deferred in patients with biochemical recurrence after radical prostatectomy who have negative PSMA PET-CT and pelvic MRI.
